Financial Results & Release Schedules, Stock Performance Update, and New Clinical Trials - Research Report on Amgen, Boston

   Financial Results & Release Schedules, Stock Performance Update, and New
    Clinical Trials - Research Report on Amgen, Boston Scientific, ACADIA
                Pharmaceuticals, Seattle Genetics, and Volcano

Editor Note: For more information about this release, please scroll to bottom

PR Newswire

NEW YORK, October 29, 2013

NEW YORK, October 29, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Amgen,
Inc. (NASDAQ: AMGN), Boston Scientific Corporation (NYSE: BSX), ACADIA
Pharmaceuticals Inc. (NASDAQ: ACAD), Seattle Genetics, Inc. (NASDAQ: SGEN),
and Volcano Corporation (NASDAQ: VOLC). Today's readers may access these
reports free of charge - including full price targets, industry analysis and
analyst ratings - via the links below.

Boston Scientific Corporation Research Report

On October 24, 2013, Boston Scientific Corporation (Boston Scientific)
reported its Q3 2013 financial results. The Company's net sales remained
unchanged at $1.7 billion during the quarter on YoY basis. Net loss was $5
million or $0.00 per diluted share in Q3 2013, compared to net loss of $664
million or $0.48 per diluted share in Q3 2012. Commenting on the results, Mike
Mahoney, Boston Scientific's President and CEO, said, "We are pleased with our
strong overall results and the momentum we are building globally in a dynamic
healthcare environment. We accelerated our operational performance in the
quarter while enhancing our ability to deliver meaningful innovation to our
customers and their patients." Additionally, the Company announced that
Jeffrey Capello, Boston Scientific's Executive Vice President and CFO, will
transition out of the role, effective December 31, 2013, while Daniel Brennan
will take over his responsibilities, effective January 1, 2014. Meanwhile,
Capello is expected to remain with the Company as a Senior Advisor until
mid-May 2014. The Full Research Report on Boston Scientific Corporation -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/5640_BSX]

--

Amgen, Inc. Research Report

On October 22, 2013, Amgen, Inc. (Amgen) reported its Q3 2013 financial
results. The Company's total revenues increased 9.9% YoY to $4.7 billion
during the quarter. The Company's net income was $1.4 billion or $1.79 per
diluted share in Q3 2013, compared to net income of $1.1 billion or $1.41 per
diluted share in Q3 2012. Commenting on the results, Robert A. Bradway,
Chairman and CEO of Amgen, said, "We delivered excellent operating performance
this quarter. We also delivered excellent strategic progress with the
acquisition of Onyx Pharmaceuticals in oncology, the opening of our alliances
in Japan and China, and the repurchase of our rights to NEUPOGEN and Neulasta
in key emerging growth markets around the world." The Full Research Report on
Amgen, Inc. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/e96b_AMGN]

--

ACADIA Pharmaceuticals Inc. Research Report

On October 24, 2013, ACADIA Pharmaceuticals Inc.'s (ACADIA Pharmaceuticals)
stock gained 12.31%, ending the day at $24.73. Over the previous three trading
sessions, shares of ACADIA Pharmaceuticals gained 7.20%, outperforming the
Nasdaq Composite which gained 0.23% during the same period. The Full Research
Report on ACADIA Pharmaceuticals Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.analystscorner.com/r/full_research_report/3eb7_ACAD]

--

Seattle Genetics, Inc. Research Report

On October 21, 2013, Seattle Genetics, Inc. (Seattle Genetics) announced the
initiation of a phase 1 clinical trial evaluating SGN-LIV1A for patients with
LIV-1-positive metastatic breast cancer. The Company said that SGN-LIV1A uses
Seattle Genetics' antibody-drug conjugate (ADC) technology, and the trial is
meant to assess the safety and antitumor activity of SGN-LIV1A, an ADC
targeted to LIV-1 (SLC39A6), a protein which is expressed in most subtypes of
metastatic breast cancer. Jonathan Drachman, M.D., Chief Medical Officer and
Executive Vice President, Research and Development, at Seattle Genetics, said,
"ADCs represent a novel treatment approach that have demonstrated activity in
both hematologic and solid tumors. SGN-LIV1A is one of four ADCs that we are
advancing into the clinic during 2013, demonstrating our significant
investment in this approach for the treatment of cancer. The target expression
in breast cancer, preclinical antitumor activity, and need for novel
therapeutic options for advanced breast cancer patients all support the
clinical evaluation of SGN-LIV1A." The Full Research Report on Seattle
Genetics, Inc. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/ff98_SGEN]

--

Volcano Corporation Research Report

On October 21, 2013, Volcano Corporation (Volcano) announced that the Company
will report its operating results for Q3 2013 on Monday, November 4, 2013. The
Company stated that it will also hold a conference call to discuss its
financial results and operating activities on the same day at 2:00 p.m. PST
(5:00 p.m. EST), hosted by Volcano's President and CEO, Scott Huennekens and
CFO John Dahldorf. The Full Research Report on Volcano Corporation - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.analystscorner.com/r/full_research_report/14bf_VOLC]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we
    are only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Namrata Maheshwari,
CFA, has only reviewed the information provided by Equity News Network in this
article or report according to the Procedures outlined by Equity News Network.
Equity News Network is not entitled to veto or interfere in the application of
such procedures by the outsourced provider to the articles, documents or
reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

AnalystsCorner.com

SOURCE Analysts' Corner

Contact: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North America)